Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients…

Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis

 

Conducted for the British Columbia Ministry of Health

Tricco, A. C., Ashoor, H. M., Antony, J., Beyene, J., Veroniki, A. A., Isaranuwatchai, W., ... & Catherine, H. Y. (2014). Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: Systematic review and network meta-analysis. BMJ, 349, g5459. doi: 10.1136/bmj.g5459.

 

Impact:

  • Influenced the decision to continue listing the insulin in the same manner for the province of British Columbia
  • Featured in >220 mass media articles
Printer Friendly

Category :

Date : 22 Mar 2016